[Bempedoic acid and inclisiran : two new drugs to treat hypercholesterolemia].

Last European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines on dyslipidemia published in 2019 recommend an LDL-cholesterol goal < 1.4 mmol/l (< 55 mg/dl) for people at very high cardiovascular risk. They propose combinations of lipid lowering therapies in addition to statins if necessary to meet this objective, which is very rarely reached in this at risk population.

[Therapeutic impact of screening for myocardial ischemia among asymptomatic type 2 diabetic subjects].

Coronary artery disease is the major cause of mortality of type 2 diabetic subjects. Its early diagnosis to prevent progression and clinical events has intuitive appeal. Somehow, rationale for screening has not been clearly established.